Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:SMMT 19 October 2025 - 14 January 2026

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK shares rose about 0.4% in early London trading after Summit Therapeutics announced a clinical trial collaboration to test ivonescimab with GSK’s experimental B7-H3 cancer drug. Patient dosing is expected to begin in mid-2026. GSK will report full-year results on Feb. 4. Senior managers recently acquired small amounts of GSK shares through company plans.
14 January 2026
···
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics shares fell 11% to $17.46 Monday after announcing a U.S. FDA biologics license application for its lung cancer drug ivonescimab. The company also disclosed a clinical trial collaboration with GSK to test a combination regimen in solid tumors. Investors are watching for the FDA’s next procedural step and updates from the J.P. Morgan Healthcare Conference.
12 January 2026
·
Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Dyne Therapeutics shares fell 16.9% to $18.44 after announcing a $300 million stock offering. SLM Corp dropped 15%, Kontoor Brands slid 9.5%, and Waystar Holding lost 8.4%. Major indexes were little changed as investors awaited the Federal Reserve’s interest-rate decision. The U.S. 10-year Treasury yield hovered near 4.19%.
10 December 2025
···········
Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility

Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility

Summit Therapeutics shares traded at $17–18 on December 9, 2025, near the low end of their 52-week range of $15.55 to $36.91. The company’s lung cancer drug ivonescimab recently outperformed Keytruda in a limited trial, drawing attention but also regulatory questions. Summit granted inducement stock options to new hires on December 5. The company’s market cap stands near $13–14 billion.
9 December 2025
·
Summit Therapeutics (SMMT) Skyrockets on Cancer Breakthrough – Key Facts & Outlook

Summit Therapeutics (SMMT) Skyrockets on Cancer Breakthrough – Key Facts & Outlook

Summit Therapeutics’ stock closed at $20.99 on Oct. 17, up 16% in the past month and 14% year-to-date, with a market cap near $15.6 billion. On Oct. 19, Summit reported Phase 3 trial data showing its cancer drug ivonescimab plus chemo cut lung cancer progression or death risk by 40% versus a standard treatment. The company is expanding trials into colorectal cancer and other tumor types. Q3 earnings and further data updates are expected today.
20 October 2025
·
Summit Therapeutics (SMMT) Stock Soars on Cancer Breakthrough – Can the Biotech’s Rally Hold?

Summit Therapeutics (SMMT) Stock Soars on Cancer Breakthrough – Can the Biotech’s Rally Hold?

Summit Therapeutics reported positive Phase 3 results for its cancer drug ivonescimab on Oct. 19, reducing disease progression risk by 40% in a key lung cancer trial. Shares closed at $20.99 on Oct. 17, down 4.5% that day but up 14% year-to-date. The company’s market cap stands near $15.6 billion after a 1,770% three-year surge. Summit will report Q3 earnings and present new data at ESMO on Oct. 20.
19 October 2025
·

Stock Market Today

  • Lessons from This Week's Crude Oil Plunge and Stock Spike
    April 9, 2026, 6:36 AM EDT. This week saw a dramatic plunge in crude oil prices followed by a sharp spike in stocks, highlighting three key lessons for investors. First, market volatility remains high amid global economic uncertainties. Second, oil price fluctuations can trigger rapid shifts in equity markets, emphasizing the interconnectedness of commodities and stocks. Third, trading strategies like TACO (Trade And Commodity Options) demonstrate the importance of flexible approaches in navigating unpredictable market movements. Investors should stay alert to these dynamics to manage risk effectively.

Latest article

India Stock Market Today: Sensex Drops Over 1,100 Points, Nifty Slips as Oil Rebound Revives Risk Fears

India Stock Market Today: Sensex Drops Over 1,100 Points, Nifty Slips as Oil Rebound Revives Risk Fears

9 April 2026
Indian stocks fell sharply Thursday afternoon, with the Sensex down 1.51% and the Nifty 50 off 1.12% as oil prices rebounded and U.S.-Iran ceasefire concerns resurfaced. Financials and IT shares led declines, with HDFC Bank, SBI, and ICICI Bank losing up to 2.27%. The World Bank warned the West Asia crisis threatens India’s growth and inflation outlook. India imports about 90% of its oil.
Australia Stock Market Today: ASX 200 Ends at Five-Week High as Banks Offset Tech Rout

Australia Stock Market Today: ASX 200 Ends at Five-Week High as Banks Offset Tech Rout

9 April 2026
The S&P/ASX 200 closed up 0.2% at 8,973.20 on Thursday, a five-week high, led by gains in banks while tech shares slumped. Bendigo and Adelaide Bank surged 9.5% after reporting higher earnings and job cuts. Energy stocks rose as oil rebounded, but trading volumes stayed below average. Investors remained cautious amid ongoing Middle East tensions and uncertain oil supply routes.
UK Stock Market Today: FTSE 100 Holds Near 10,600 as Oil Rebound Tests Ceasefire Rally

UK Stock Market Today: FTSE 100 Holds Near 10,600 as Oil Rebound Tests Ceasefire Rally

9 April 2026
FTSE 100 held near 10,600 Thursday after a 2.5% rally to a one-month high, outperforming European peers as Germany’s DAX and France’s CAC 40 fell. Brent crude rebounded toward $98 on renewed U.S.-Iran ceasefire doubts. A Bank of England survey showed lenders expect mortgage demand to rise in Q2. British builders faced record cost inflation in March.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 6:36 AM EDT Lessons from This Week's Crude Oil Plunge and Stock Spike April 9, 2026, 6:36 AM EDT. This week saw a dramatic plunge in crude oil prices followed by a sharp spike in stocks, highlighting three key lessons for investors. First, market volatility remains high amid global economic uncertainties. Second, oil price fluctuations can trigger rapid shifts in equity markets, emphasizing the interconnectedness of commodities and stocks. Third, trading strategies like TACO (Trade And Commodity Options) demonstrate the importance of flexible approaches in navigating unpredictable market
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Go toTop